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linical Significance of Early Thrombosis
fter Prosthetic Mitral Valve Replacement
Postoperative Monocentric Study of 680 Patients
uillaume Laplace, MD, Ste´phane Lafitte, MD, PHD, Jean-Noe`l Labe`que, MD, Jean-Marie Perron, MD,
uge`ne Baudet, MD, Claude Deville, MD, Xavier Roques, MD, Raymond Roudaut, MD, FESC
hu de Bordeaux, Pessac, France
OBJECTIVES The aim of this study was to evaluate the incidence of early thrombosis, its prognostic
significance, and the therapeutic implications.
BACKGROUND Transesophageal echocardiography (TEE) is the method of choice for detecting symptomless
early postoperative thrombosis of prosthetic valves. However, the clinical significance is not
yet known.
METHODS Between June 1994 and December 2000, 680 consecutive patients underwent TEE on day 9
after mechanical mitral valve replacement, to search for early thrombosis. Initially, end points
were the in-hospital outcome and treatment. Patients were also evaluated 34  22 months
after surgery.
RESULTS Sixty-four early thrombi were detected (9.4%). Two early obstructive were treated by
redo-surgery. Sixty-two nonobstructive benefited from medical treatment. The patients were
allocated into two groups as a function of the maximum size of thrombus: 5 mm in 29
patients (group A) and 5 mm in 35 (group B). During early follow-up, we observed one
complicated course in group A and eight in group B. In the long-term survey, three
complications were noted in group A and 11 in group B. Incidence of early (p  0.027) and
long-term (p  0.04) complications were significantly different in the two subsets.
CONCLUSIONS This study confirms the incidence of early thrombi after mechanical mitral valve replacement
detected by TEE. A small (5 mm) nonobstructive thrombus seems benign, and our
experience argues in favor of medical treatment. Prognosis appears more serious for large
thrombi. Medically aggressive therapy and further surgery should be considered in cases of
obstructive thrombosis or large and mobile nonobstructive thrombosis. (J Am Coll Cardiol
2004;43:1283–90) © 2004 by the American College of Cardiology FoundationM
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cnumber of recent studies with transesophageal echocar-
iography (TEE) have identified a high incidence of non-
bstructive thrombi (NOT) in the early postoperative pe-
iod after mechanical mitral valve replacement (MMVR)
1–5). Such phenomena are known to increase morbidity
nd mortality and are often the consequence of inadequate
nticoagulant therapy in the highly unstable period after
urgery (3,6,7). Transesophageal echocardiography is cur-
ently recognized as the method of choice for detecting
bnormal echoes, especially those from NOT.
The purpose of our study was to define the incidence of
onobstructive and obstructive thrombosis after implanta-
ion of bileaflet mitral prostheses, the optimal management,
nd the short- and long-term complications of these
hrombi.
ETHODS
opulation. A total of 680 consecutive patients who ben-
fited from MMVR with a bileaflet prosthesis (Saint Jude
From the Hoˆpital Cardiologique du Haut-Le´veˆque, Chu de Bordeaux, Pessac,
rance. Robert A. O’Rourke, MD, acted as the guest editor for this paper.
Manuscript received March 13, 2003; revised manuscript received August 19, 2003,mccepted September 23, 2003.edical, MIRA, ATS, SORIN) from June 1994 to De-
ember 2000 in our institution were included in this
rospective, monocentric study. All patients underwent
ystematic, early TEE on day 9 after surgery. The postop-
rative anticoagulant treatment consisted of intravenous
eparin started 6 h after implantation and adjusted from the
ctivated partial thromboplastin time (aPTT). This was
ollowed at the 24th h by subcutaneous heparin three times
day, which was prolonged until the target international
ormalized ratio (INR  2.5 to 3.5) was obtained with oral
nticoagulant therapy (fluindione), started at day 2. The first
19 patients were randomized in a prospective study to
etermine the effect of a low dose of aspirin (200 mg) in the
ostoperative period (8). The other 461 patients did not
eceive any antiplatelet therapy.
chocardiography. Transesophageal echocardiography
as performed in the early postoperative period in all
atients, using a Hewlett-Packard Sonos 2500 or 5000
Hewlett-Packard Imaging System, Andover, Massachu-
etts) and Acuson Sequoia (Acuson, Mountain View, Cal-
fornia) connected to a multiplane 5-7 Mhz probe. All TEE
ere recorded on videotapes and reexamined twice. We
arefully examined the atrial and ventricular side of the
itral prosthesis, looking for leaflet dysfunction, mitral
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Early Thrombi After Mitral Valve Surgery April 7, 2004:1283–90egurgitation, spontaneous echocardiography contrast
SEC), strands, and thrombi. A strand was defined as a
inear, mobile, and thin (1 mm) echo attached to the atrial
ide of the prosthesis. A thrombus was defined as an
bnormal well circumscribed mobile or immobile mass
sually found in the vicinity of the mitral valve annulus. All
haracteristics of the thrombi were analyzed to specify size,
orm, localization, and mobility.
In accordance with the report of Gue´ret et al. (3), thrombi
ere defined as small when their maximal length was5 mm
group A) and large when the length was 5 mm (group B).
herapeutic approach and survey of thrombus. The ther-
py of the thrombi was left to the discretion of each surgical
eam and was analyzed retrospectively. Clinical follow-up,
ccording to published recommendations (9), included total
nd cardiac mortality, along with morbid events: symptom-
tic embolic event (stroke, transient ischemic attack [TIA]
f less than 24 h duration, peripheral embolism), prosthetic
bstruction, and treatment complications such as hemor-
hage. Transesophageal echocardiography monitoring was
eft to the discretion of the surgical and medical teams and
as carried out in about half the cohort.
ollow-up. Early clinical course (one month) was studied
uring the in-hospital period. Long-term follow-up was
onducted by telephone or letter contact to the consulting
hysicians at 34  22 months since implantation.
tatistical analysis. All data are expressed as mean  1 SD.
ualitative values were compared by Fischer exact test. Un-
aired Student t test was used to the quantitative variables
nalysis. The p value indicating statistical significance was set
t 0.05.
ESULTS
arly systematic postoperative TEE (day 9) was performed
n 680 patients from June 1994 to December 2000, revealing
n 64 patients the presence of one or more abnormal masses
n the prosthesis interpreted as local thrombus (9.4%).
The cohort comprised 33 women and 31 men with a
ean age of 64  9 years (range, 39 to 82 years) (Table 1).
At the time of the TEE, all patients were treated by oral
nticoagulation (fluindione), and 31 of them (47%) were
till treated by subcutaneous or intravenous heparin when
NR targets had not been reached.
Abbreviations and Acronyms
aPTT  activated partial thromboplastin time
INR  international normalized ratio
MMVR  mechanical mitral valve replacement
NOT  nonobstructive thrombus
OT  obstructive thrombus
SEC  spontaneous echocardiographic contrast
TEE  transesophageal echocardiography
TIA  transient ischemic accident
TTE  transthoracic echocardiographyThe bileaflet valve was a St. Jude Medical prosthesis (St. maul, Minnesota) in 38 cases, ATS (AB Medical, Minne-
polis, Minnesota) for 14 patients, SORIN (Saluggia, Italy),
nd MIRA (Edwards Lifesciences, Mairepas, France) in six
ases.
On day 9, only two patients were symptomatic: one
resented with nonfatal stroke and the other with conges-
ive heart failure (New York Heart Association class 4).
owever, these two patients presented a NOT on the
rosthesis. Sixty-two others patients were either asymptom-
tic or had minor aspecific symptoms.
In two asymptomatic patients, transthoracic echocardi-
graphy (TTE) and TEE detected early OT, measuring
ore than 10 mm, and both were treated by redo-surgery
one mechanical valve, one bioprosthetic valve).
In the other 62 patients, transthoracic examination sug-
ested normal function of the bileaflet prosthesis (no sig-
ificant dysfunction of the poppet, no increase in transval-
ular mean gradient). In many of them, TEE showed
trands or spontaneous contrast echoes, but these phenom-
na were not considered as pathologic in our study.
chographic characteristics of thrombi. SIZE. Maximum
iameter of thrombus was less than 5 mm in 29 cases (45.3%)
Figs. 1 and 2). Thrombus size was from 5 to 10 mm in 28
atients (43.7%), and thrombi of more than 10 mm were
etected in seven patients (11%) including the two initial
bstructive ones.
OCALIZATION. Sixty-two thrombi were attached to the
trial side of the prosthesis (on the sewing ring or on the
oppet), but we also found four thrombi on the ventricular
ide of the annulus.
ORM. The abnormal mass was localized and round in 40
ases, and circumferential in 24 patients.
OBILITY. Thirty-six thrombi (56%) were sessile and im-
igure 1. Transesophageal echocardiography showing two round nonob-
tructive thrombi on the atrial side of the sewing ring of the mitral
rosthesis.obile; 28 (44%) were pedunculated and slightly mobile.
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April 7, 2004:1283–90 Early Thrombi After Mitral Valve SurgeryREDISPOSING FACTORS. Two predisposing factors of early
hrombosis were analyzed: atrial fibrillation was found in 26
atients of 64 (41%) before or immediately after surgery.
ixteen patients (25%) were operated with an impaired left
entricle ejection fraction (50%), and the association of
oth factors was observed in eight patients (12%). Three
atients were implanted with a pacemaker in the postoper-
tive period, and the anticoagulant therapy was, therefore,
iscontinued for a few hours.
HERAPEUTIC APPROACHES. Immediate therapy after the
iscovery of early postoperative thrombus was left to the
iscretion of each surgical team: the decision for reinter-
ention was based on clinical and echographic data. The
wo early obstructive thrombi were immediately reoper-
ted because of the major risk of complication; medical
reatment was readjusted in all of the remaining cases of
arly NOT. Intravenous or subcutaneous heparin was
einitiated in 33 patients (53%) monitored by the aPTT.
simple readjustment and optimization of the oral
nticoagulation (vitamin K antagonist therapy) with a
arget INR 3 was proposed for 19 patients (31%).
spirin was added in 13 cases and nonsteroid anti-
nflammatory therapy in seven patients.
linical course of patients with early thrombi. Immediate
1 month) and long-term (1 year) outcomes were
nalyzed in the cohort of 64 patients exhibiting an early
hrombus after MVR (Table 1). The mean duration of
ollow-up was 34  22 months and was obtained for the
ajority of patients, with only two lost to follow-up during
he first year.
arly course (one month). In group A (small thrombus,
 29), we only observed one early (first month of
ollow-up) complicated course (3.4%): one patient had a
IA (defined as a neurologic syndrome of less than 24 h
uration) and died of heart failure at postoperative day 15
Patient 8).
igure 2. Same transesophageal echocardiography as in Figure 1 but with
perpendicular view. Thrombus finally appears annular and immobile.Among the 35 patients of group B (large thrombus, n  t5), the early course seemed to be more serious. Two early
bstructive thrombi were immediately reoperated, which is
ecognized as a complicated course (Patient 42 and Patient
3); in the other 33 patients with large NOT, six presented
evere events: three strokes, defined as a sudden focal brain
ysfunction lasting more than 24 h (Patients 2, 7, and 53),
nd two secondary enlargements, finally becoming obstruc-
ive in the first month despite anticoagulant therapy, and
equiring redo-surgery (Patients 21 and 24); one of these
atient died of multiple organ failure during the first month.
n this cohort, we also observed another early fatal event: a
atient with two NOT measuring 5 mm died as a result of
astrointestinal bleeding (Patient 13). In total, eight of the
5 patients with large thrombi presented an early (first
onth) complicated course (22%).
ong-term course (more than one year). Over the whole
ollow-up period (mean duration: 34  22 months), we
bserved two other complications in group A: two late TIA
Patient 19 in the second and Patient 40 in the fourth
onth). In group B, a trend for more serious complications
as noted: two late nonfatal strokes (Patients 9 and 52) and
hree other deaths in this cohort. One patient with an early
troke died six months later (Patient 2), and another of heart
ailure at month 6 (Patient 41). One of the two patients
ith early OT, despite redo-surgery, presented a fatal course
2 weeks after MMVR (Patient 42).
It is of note that a patient with an early stroke had
nother neurological ischemic event five years later. In this
atient, a small thrombus was seen on the valve, but this
vent was not recorded as a complication because of the
isappearance of the first thrombus on TEE examination
ve months after implantation. Total mortality was esti-
ated at 9.4% (six patients) in the long-term survey (three
arly and three late deaths), and five of these six patients
ere in group B.
Finally, in group A, the follow-up revealed a complicated
ourse for 3.4% of patients in the first month and for 10%
ver the total duration of the study. In group B, complica-
ions occurred in 22% of patients in the early period and in
1% over the long-term survey. Complications were signif-
cantly more frequent during the early (p  0.027) and
ong-term (p  0.04) follow-up periods in the group of
atients with large thrombi (group B).
From another viewpoint, we could split this large cohort
nto two different subsets: the first of 54 patients with an
arly (1 month) uneventful course (in this group, mean
ize of thrombus  5.56  3.3 mm). The second group
omprised 10 patients presenting an early complication after
iagnosis of early thrombosis, whose mean lengths (8.95 
.3 mm) were significantly higher than those of the first
roup (p  0.0009). A significant difference was also noted
etween these two subsets in the long-term follow-up. We
oncluded that the early and long-term course appeared to
epend on the initial size of the thrombus with a higher
ncidence of events (principally embolic accidents) for pa-
ients with large, often asymptomatic thrombi. These results
Table 1. Summary of 64 Cases of Early Postoperative Thrombosis After MMVR: Demographic, Echographic, and Clinical Data
Pt.
No. Gender Age
Type
of
Valve Risk Factor
Initial
Symptoms
Size of
Thrombus
(mm) Obstruction Treatment
Follow-Up
(Month)
Evolution
TEE SurveyShort-Term Long-Term
1 M 69 SJM AF/imp LVEF 9 Hep-OAC
readjusted
68 Dis at 6 months
2 F 75 SJM AF/imp LVEF 7 OAC-asp 6 Stroke Death at 6
months
3 F 82 SJM 5 Hep-OAC 66
4 F 70 SJM 5 Hep-OAC 65 Per at 6 months
Dis at 7 months
5 F 61 SJM 3 Hep-OAC 62 Dis at 6 months
6 F 61 SJM AF 3 Hep-OAC 54 Dis at 6 months
7 F 66 SJM Stroke at day 7 6 OAC 84 Stroke TIA 5 years
later
Dis at day 7
8 F 70 SJM Imp LVEF 3 OAC 0.5 TIA-death
9 M 67 SJM AF 6 OAC-asp-NSAI 69 Stroke Per at 6 months
10 M 55 SJM 3 OAC-asp 70 Dis at 5 months
11 F 40 SJM AF/imp LVEF 3 OAC-asp 60 Dis at 5 months
12 F 66 SJM AF/imp LVEF 4.5 OAC 69 Dis at 6 months
13 M 67 SJM 5 OAC 1 Death by
GIB
14 F 74 SJM 4 OAC 53 Dis at 5 months
15 M 71 SJM AF 2 Hep-OAC 76 Dis at 5 months
16 F 70 SJM 2 Hep-OAC 52 Dis at 5 months
17 M 66 SJM AF 4 Hep-OAC-asp 6 Dis at 6 months
18 M 55 SJM Imp LVEF 4 Hep-OAC 52 Dis at 6 months
19 F 67 SJM 3 Hep-OAC-asp 53 TIA at 2
months
Per at 5 months
20 M 63 SJM Imp LVEF/PM 20 Hep-OAC 49
21 F 71 SJM 14 Secondary Obs Hep-OAC-redo-
surgery
1 Obs death
22 F 68 SJM Imp LVEF 10 Hep-OAC 52 Dis at 5 months
23 M 60 SJM 7 OAC 41
24 F 73 SJM Heart failure 10 Secondary Obs Hep-redo-surgery 40 Obs heart
failure
25 F 58 SJM AF 4 OAC 64
26 M 59 SJM 3 Hep-OAC-asp 37
27 M 54 SJM AF 3 OAC 12
28 M 54 SJM 8 20 Dis at 5 months
29 M 75 Sorin PM 11 Hep-OAC 29 Dis at 5 months
30 M 57 Sorin AF 4 Hep-OAC-asp Lost Per at 1 month
31 M 60 SJM AF 4 OAC 28
32 M 68 Sorin 4 Hep-OAC 27 Dis at 1 month
33 M 67 ATS Imp LVEF 12 Hep-OAC-asp 27 Per at 2 months
34 F 67 Sorin 5 OAC 28 Dis at 5 months
Continued on next page
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Table 1. Continued
Pt.
No. Gender Age
Type
of
Valve Risk Factor
Initial
Symptoms
Size of
Thrombus
(mm) Obstruction Treatment
Follow-Up
(Month)
Evolution
TEE SurveyShort-Term Long-Term
35 F 58 Sorin 8 Hep-OAC 25
36 M 50 Sorin AF/imp LVEF 7 Hep-OAC 52 Dis at 1 month
37 M 75 Sorin AF 4 Hep-OAC 26
38 F 54 SJM AF 6 OAC Lost
39 M 73 ATS AF 4 Hep-OAC-asp 25 Dis at 1 month
40 F 65 Mira AF 2 OAC 24 TIA at 4 months
41 M 72 ATS AF 6 OAC-asp 6 Death at 6 months
42 M 72 ATS Imp LVEF/PM 11 Initial Obs Redo-surgery 4 Death at 4 months
43 F 58 SJM AF/imp LVEF 5 OAC 48
44 F 59 Mira AF 3 OAC 45
45 F 77 Mira AF/imp LVEF 5 Hep-OAC 33
46 M 39 ATS Imp LVEF 4 OAC 30
47 M 51 SJM 6 OAC-asp-NSAI 42
48 F 68 ATS 10 OAC 12
49 F 65 Mira AF 5 OAC 14 Dis at 1 year
50 M 47 SJM Imp LVEF 10 Hep-OAC 14
51 F 60 ATS 7 OAC 12
52 F 60 ATS 12 Hep-OAC-asp 16 Stroke at 5 month Dis at 7 months
53 M 73 ATS 10 Hep-OAC 15 Stroke at 1st
month
Dis at 3 months
54 F 49 ATS 6 Hep-OAC 11
55 M 62 SJM AF 11 Hep-OAC-NSAI 29 Dis at 1 month
56 M 70 ATS 2 OAC-NSAI 28
57 F 45 Mira AF 3 Hep-OAC-NSAI 28
58 M 69 ATS 5 Hep-OAC 12 Decrease at 1
month
59 M 66 SJM AF/imp LVEF 2 OAC-asp 12
60 F 77 SJM 3 Hep-OAC 12
61 M 59 ATS 2 OAC 27
62 F 71 Mira AF 6 Hep-OAC 24 Dis at 1 month
63 F 71 ATS 20 Initial Obs Redo-surgery 1
64 F 52 SJM 8 Hep-OAC 40 Decrease at day 8
AF atrial fibrillation; asp aspirin; Dis disappearance; F female; GIB gastrointestinal bleeding; Hep heparin; imp LVEF impaired left ventricle ejection fraction; Mmale; MMVRmechanical mitral valve replacement;
NSAI nonsteroid anti-inflammatory; Obs obstruction; OAC oral anticoagulation; Per persistence; PM pacemaker implantation; Pt. No. patient number; TEE transesophageal echocardiography; TIA transient ischemic
attack.
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Early Thrombi After Mitral Valve Surgery April 7, 2004:1283–90re listed in Table 2 and Figure 3 and would indicate a
evised therapeutic approach for patients with large
hrombi.
ISCUSSION
here are numerous reports of a high incidence of postop-
rative NOT after MMVR (1–5,7). Our study represents
he largest population to date of patients benefiting from
ystematic TEE after surgery. We showed that about 10%
f these patients presented an abnormal mass usually adher-
ng to the atrial face of the prosthesis, considered as a
hrombus. It should be noted that all the patients except two
xamined in this cohort of 680 presented few or no
ymptoms on the day of early TEE.
ystematic TEE after MMVR. Diagnosis of mechanical
alve thrombosis is usually based on TTE and cinefluoros-
opy; on TTE, thrombosis can be detected from an increase
n the transvalvular mean pressure gradient measured by
oppler. A reduction in mobility or even immobility of one
f the poppets may also be evidenced. However, an increase
n this gradient is commonly seen immediately after surgery
ue to the altered hemodynamic conditions, the presence of
able 2. Early (1 Month) and Long-Term Evolution of
hrombosis as a Function of the Size
Initial Size <5 mm >5 mm p Value
arly complicated course 1 (3.3%) 8 (22%) 0.027
ong-term complicated course 3 (10%) 11 (31%) 0.04
igure 3. Early and long-term evolution of thrombi in the two groups of pa
transient ischemic accident.nemia or tachycardia, even when the prosthesis works
erfectly. On the other hand, normal transthoracic echocar-
iogram examination and fluoroscopy may not exclude
OT. Thus, TTE and cinefluoroscopy seem to be attractive
lternatives (5). However, TEE is recognized as having
uperior sensitivity and specificity for the diagnosis of mitral
rosthetic thrombi because of echocardiography artefacts in
he left atrium on TTE examination (10–14). Many studies
ave demonstrated the interest of TEE after mechanical
VR for the detection of thrombi (7–9). In our experience
n 680 patients, we observed 64 thrombi (9.4%), most of
hem nonobstructive. Our patients (except two) presented
ew symptoms indicative of thrombotic phenomena, and
heir valves were considered to be functioning normally
ased on the postoperative Doppler parameters from sys-
ematic TTE. This incidence had been demonstrated in
any prospective studies of systematic TEE after MVR.
owever, in these asymptomatic patients, we observed a
igher incidence of early and late complications, such as
ystemic embolic events (TIA, stroke) or obstruction with
eart failure. We found a relationship between the initial
ize of the thrombus and the incidence of complications.
hese observations would indicate the value for a thorough
earch for early thrombosis after MMVR, as a guide to
ostoperative management. We, therefore, recommend, as
entioned in French guidelines for the management of
atients with valvular heart diseases (15), systematic post-
perative TEE after MMVR.
. G.I.B. gastrointestinal bleeding; O.T. obstructive thrombus; T.I.A.tients
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April 7, 2004:1283–90 Early Thrombi After Mitral Valve Surgeryredisposing factors for thrombosis. Many authors have
ooked for hemodynamic or echographic factors predictive
f early thrombi after mitral surgery. Dadez et al. (2)
howed that SEC in the left atrium as detected by TEE was
ssociated with abnormal small echoes on the atrial side of
he prosthesis, which were responsible for the increase in
mbolic events. This notion was supported by Bonnefoy et
l. (4) in a study of systematic TEE 24 h after MVR. O¨zkan
16) described three independent predictors: SEC, atrial
brillation, and preoperative thrombus. However, Malergue
t al. (1) failed to evidence any statistical difference for
ncidence of atrial fibrillation, SEC, or left ventricle dys-
unction. Gue´ret (3) concluded that early thrombosis after
itral prosthesis was associated with unpaired systolic
ractional shortening and atrial parameters. According to
ung (6), small abnormal echos after MMVR are associated
ith conditions predisposing to SEC with high dose pro-
amine administration during surgery compounded by in-
dequate postoperative anticoagulation.
In a previous study in our center (7), the low level of
nticoagulation in the immediate postoperative period
merged as the principal cause of early thrombosis. Indeed,
he formation of a thrombus can be explained by an
mbalance in the parameters of Virchow (17): cardiac
urgery, especially mechanical MVR, and extracorporeal
irculation damages native tissues, while artificial surfaces
nduce variations in local rheology with stagnation of blood
nd reduction in flow velocity. A hypercoagulable state is
ften observed with platelet and leucocyte activation, with
oagulation factors and fibrinogen maintaining a vicious
ircle. All these parameters are affected by poor anticoagu-
ation, which is thought to represent the most important
isk factor (3,6,7).
herapeutic implications. Management of thrombus after
echanical MVR is still matter of debate (18). For obstruc-
ive thrombi, the major risk of complications indicates an
arly aggressive approach according to American College of
ardiology/American Heart Association guidelines (19).
ibrinolysis is contraindicated in the first 14 postoperative
ays due to risk of major bleeding (hemopericardium), but
ay be indicated at later times (18,20–26). Gue´ret (3)
ecommends systematic surgical treatment for obstructive or
arge and threatening thrombi, or failure of medical therapy
complications or thrombi growing under anticoagulant
herapy). Although redo-surgery carries a major risk of
ortality (7), we applied this strategy to the two initial and
wo secondary OT, with long-term success in three of these
atients.
The problem of management of NOT is more acute (24).
he evolution of these thrombi seems to depend on the
nitial size as found in the present study. Several authors
ave shown the importance of anticoagulation in the im-
ediate postoperative period. We also recommend the
einitialization of intravenous continue heparin monitored
y aPTT until correct adjustment of oral anticoagulation.
The value of aspirin is still unclear. Laffort et al. (8)howed that aspirin added to conventional oral anticoagu-
ation decreased the incidence of postoperative thrombi, but
ong-term prescription increased the incidence of major
leeding (gastrointestinal hemorrhage). We propose an
ssociation of anticoagulation and aspirin with gastric pro-
ection for large and mobile NOT; this group of patients
ill probably require TEE survey until disappearance of the
hrombi. However, the incidence of potential thromboem-
olic events in the subset with large thrombi might justify a
ore aggressive approach.
tudy limitations. The principal limitation of the present
tudy was the absence of randomization in the therapeutic
trategies. Each surgical team chose how to manage their
atients after diagnosis of the thrombosis, and we did not
nfluence their decisions. Apart from OT for which redo-
urgery seems essential, we could not draw any conclusions
bout optimal treatment of such early thrombi.
At the beginning of our study, a systematic TEE was
erformed at the fifth month (26 patients), but we did not
xtend this to the whole population, and so we lack
nformation on the echographic outcome of all thrombi,
specially in the patients with uneventful course.
onclusions. This study represents the largest cohort of
atients benefiting from TEE after MMVR and confirms
he high incidence (about 10%) of early postoperative, often
symptomatic, and NOT.
The course is usually benign for small thrombi (5 mm)
hen anticoagulant therapy is adapted. Patients presenting
arge NOT develop more complications and require a more
ggressive approach: reintroduction of heparin until oral
nticoagulation is well adjusted, administration of aspirin,
nd, in the most threatening large thrombi, redo-surgery.
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ervice de Cardiologie, Pr Roudaut, Hoˆpital Cardiologique du
aut-Le´veˆque, Avenue Magellan, 33604 Pessac, France. E-mail:
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